Search and Browse
Download
Enter Data
| PMID | Data | Article Title | Organization |
|---|---|---|---|
| 26005524 | 147 | Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes. |
Merck Research Laboratories |
| 17315859 | 12 | Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. |
Diatide Research Laboaratories |
| 2903246 | 58 | Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. |
University of Arizona |